NOTE - Please note this stock is trading near $1 and has a market cap of less than $100mn. Avisol Capital recommends strong due diligence and considerable second thoughts while planning to invest in such companies.
Bellicum Pharmaceuticals (BLCM) is one strange company - it continues to present strong data from its BPX-501 and ~601 product candidates, and the stock continues to slide downwards.
There was a time - a few years ago - when Bellicum was the darling of investors in the CAR-T/T cell space. With its advanced therapy-controlling rimiducid switch used